{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:24:25Z","timestamp":1791606265314,"version":"4.3.4"},"reference-count":71,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Thymic stromal lymphopoietin (TSLP) works synergistically with Th2 cytokines to regulate infection, inflammation, and metabolic homeostasis. However, their aberrant activities lead to the onset and sustaining of many types of allergic inflammatory diseases. While biologics drug molecules blocking either TSLP or IL-4\/IL-13 show clinical efficacies, the broader effect of simultaneously targeting these cytokines remains to be explored. We generated a bispecific antibody (BsAb) targeting both TSLP and IL-4R\u03b1, which effectively blocked the signaling cascades driven by TSLP, IL-4, and IL-13. The BsAb also neutralized TSLP-driven CD4+ T cell proliferation as well as IL-4 and IL-13-driven TF-1 cell proliferation. The BsAb reduced CCL17 release from CD14+ monocytes activated by LPS, TSLP, and IL-4 and reduced allergen-induced CCL26 and IL-5 release from co-cultures of PBMC, MRC-5, and A549 cells. In a TSLP\/OVA-induced asthma model with transgenic human TSLP, TSLP receptor, IL-4, and IL-4R\u03b1 mice, the BsAb reduced every single allergic\/inflammatory hallmark, while the single target blockade antibody failed to have such comprehensive effects. Our data suggested that simultaneous blocking of TSLP, IL-4, and IL-13 could offer broader control of allergic inflammation, which could translate to a more effective treatment of related disorders.<\/jats:p>","DOI":"10.3390\/cells14221747","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:56:45Z","timestamp":1762513005000},"page":"1747","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Bispecific Antibody Blocking Both TSLP and IL-4R\u03b1 for the Treatment of Allergic Inflammatory Diseases"],"prefix":"10.3390","volume":"14","author":[{"given":"Mingcan","family":"Yu","sequence":"first","affiliation":[{"name":"Tavotek Biotherapeutics Inc., 727 Norristown Road, Building 3, Suite 101, Ambler, PA 19002, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[{"name":"Tavotek Biotherapeutics Inc., 999 Yinshanhu Road, Wuzhong District, Suzhou 215000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jin","sequence":"additional","affiliation":[{"name":"Tavotek Biotherapeutics Inc., 999 Yinshanhu Road, Wuzhong District, Suzhou 215000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Tavotek Biotherapeutics Inc., 999 Yinshanhu Road, Wuzhong District, Suzhou 215000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Tavotek Biotherapeutics Inc., 999 Yinshanhu Road, Wuzhong District, Suzhou 215000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulai","family":"Zhou","sequence":"additional","affiliation":[{"name":"Tavotek Biotherapeutics Inc., 999 Yinshanhu Road, Wuzhong District, Suzhou 215000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark L.","family":"Chiu","sequence":"additional","affiliation":[{"name":"Tavotek Biotherapeutics Inc., 727 Norristown Road, Building 3, Suite 101, Ambler, PA 19002, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1147-9444","authenticated-orcid":false,"given":"Di","family":"Zhang","sequence":"additional","affiliation":[{"name":"Tavotek Biotherapeutics Inc., 727 Norristown Road, Building 3, Suite 101, Ambler, PA 19002, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41577-022-00735-y","article-title":"Role of thymic stromal lymphopoietin in allergy and beyond","volume":"23","author":"Leonard","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2021.02.016","article-title":"The basic immunology of asthma","volume":"184","author":"Hammad","year":"2021","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"eaam8858","DOI":"10.1126\/scisignal.aam8858","article-title":"TSLP signaling in CD4+ T cells programs a pathogenic T helper 2 cell state","volume":"11","author":"Rochman","year":"2018","journal-title":"Sci. Signal."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/B978-0-12-404717-4.00004-4","article-title":"The biology of thymic stromal lymphopoietin (TSLP)","volume":"66","author":"Ziegler","year":"2013","journal-title":"Adv. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev.immunol.25.022106.141718","article-title":"TSLP: An epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation","volume":"25","author":"Liu","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.coph.2008.03.002","article-title":"Thymic stromal lymphopoietin: A new cytokine in asthma","volume":"8","author":"Rochman","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/ni1558","article-title":"A mechanism for the initiation of allergen-induced T helper type 2 responses","volume":"9","author":"Sokol","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Markovic, I., and Savvides, S.N. (2020). Modulation of Signaling Mediated by TSLP and IL-7 in Inflammation, Autoimmune Diseases, and Cancer. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01557"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nsmb.2794","article-title":"Structural basis of the proinflammatory signaling complex mediated by TSLP","volume":"21","author":"Verstraete","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"bau007","DOI":"10.1093\/database\/bau007","article-title":"TSLP signaling pathway map: A platform for analysis of TSLP-mediated signaling","volume":"2014","author":"Zhong","year":"2014","journal-title":"Database"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1515\/bc.2010.029","article-title":"Signal transduction by the atopy-associated human thymic stromal lymphopoietin (TSLP) receptor depends on Janus kinase function","volume":"391","author":"Wohlmann","year":"2010","journal-title":"Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"19455","DOI":"10.1073\/pnas.1008271107","article-title":"Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling","volume":"107","author":"Rochman","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ni805","article-title":"Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP","volume":"3","author":"Soumelis","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jaci.2012.07.010","article-title":"Thymic stromal lymphopoietin and allergic disease","volume":"130","author":"Ziegler","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.4049\/jimmunol.168.7.3288","article-title":"Uncoupling of proliferation and Stat5 activation in thymic stromal lymphopoietin-mediated signal transduction","volume":"168","author":"Isaksen","year":"2002","journal-title":"J. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1126\/science.282.5397.2258","article-title":"Interleukin-13: Central mediator of allergic asthma","volume":"282","author":"Luyimbazi","year":"1998","journal-title":"Science"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nri3831","article-title":"Type 2 cytokines: Mechanisms and therapeutic strategies","volume":"15","author":"Wynn","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1146\/annurev.immunol.17.1.701","article-title":"The IL-4 receptor: Signaling mechanisms and biologic functions","volume":"17","author":"Nelms","year":"1999","journal-title":"Annu. Rev. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jaci.2006.06.041","article-title":"IL-13 receptor alpha 2: A regulator of IL-13 and IL-4 signal transduction in primary human fibroblasts","volume":"118","author":"Andrews","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cell.2007.12.030","article-title":"Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4\/13 system","volume":"132","author":"LaPorte","year":"2008","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1172\/JCI7325","article-title":"An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response","volume":"104","author":"Chiaramonte","year":"1999","journal-title":"J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1074-7613(00)80439-2","article-title":"Stat6 is required for mediating responses to IL-4 and for development of Th2 cells","volume":"4","author":"Kaplan","year":"1996","journal-title":"Immunity"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/380627a0","article-title":"Essential role of Stat6 in IL-4 signalling","volume":"380","author":"Takeda","year":"1996","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"ra17","DOI":"10.1126\/scisignal.1164795","article-title":"Type I IL-4Rs selectively activate IRS-2 to induce target gene expression in macrophages","volume":"1","author":"Heller","year":"2008","journal-title":"Sci. Signal."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaci.2012.06.034","article-title":"IL-13 in asthma and allergic disease: Asthma phenotypes and targeted therapies","volume":"130","author":"Ingram","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cyto.2015.01.038","article-title":"History of interleukin-4","volume":"75","author":"Paul","year":"2015","journal-title":"Cytokine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cyto.2015.05.014","article-title":"IL-4 and IL-13 signaling in allergic airway disease","volume":"75","author":"Gour","year":"2015","journal-title":"Cytokine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1172\/JCI5909","article-title":"Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production","volume":"103","author":"Zhu","year":"1999","journal-title":"J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2147\/JAA.S275039","article-title":"Targeting TSLP in Asthma","volume":"15","author":"Parnes","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","article-title":"The Cytokines of Asthma","volume":"50","author":"Lambrecht","year":"2019","journal-title":"Immunity"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"220144","DOI":"10.1183\/16000617.0144-2022","article-title":"Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD","volume":"32","author":"Calderon","year":"2023","journal-title":"Eur. Respir. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7697699","DOI":"10.1155\/2023\/7697699","article-title":"The Role of TSLP in Atopic Dermatitis: From Pathogenetic Molecule to Therapeutical Target","volume":"2023","author":"Luo","year":"2023","journal-title":"Mediat. Inflamm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/s41590-019-0524-9","article-title":"TSLP: From allergy to cancer","volume":"20","author":"Corren","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.jaci.2023.02.025","article-title":"Thymic stromal lymphopoietin rather than IL-33 drives food allergy after epicutaneous sensitization to food allergen","volume":"151","author":"Brandt","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.autrev.2016.09.014","article-title":"Insight into the role of TSLP in inflammatory bowel diseases","volume":"16","author":"Park","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jaci.2014.04.022","article-title":"Thymic stromal lymphopoietin links keratinocytes and dendritic cell-derived IL-23 in patients with psoriasis","volume":"134","author":"Volpe","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.4081\/dr.2019.8006","article-title":"Skin tissue expression and serum level of thymic stromal lymphopoietin in patients with psoriasis vulgaris","volume":"11","author":"Suwarsa","year":"2019","journal-title":"Dermatol. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bbrc.2007.03.081","article-title":"A possible role for TSLP in inflammatory arthritis","volume":"357","author":"Koyama","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/art.38338","article-title":"Thymic stromal lymphopoietin, a novel proinflammatory mediator in rheumatoid arthritis that potently activates CD1c+ myeloid dendritic cells to attract and stimulate T cells","volume":"66","author":"Moret","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Protti, M.P., and De Monte, L. (2020). Thymic Stromal Lymphopoietin and Cancer: Th2-Dependent and -Independent Mechanisms. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.02088"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cytogfr.2018.12.001","article-title":"Interleukin-13: A promising therapeutic target for autoimmune disease","volume":"45","author":"Mao","year":"2019","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Iwaszko, M., Bialy, S., and Bogunia-Kubik, K. (2021). Significance of Interleukin (IL)-4 and IL-13 in Inflammatory Arthritis. Cells, 10.","DOI":"10.3390\/cells10113000"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","article-title":"Effects of an anti-TSLP antibody on allergen-induced asthmatic responses","volume":"370","author":"Gauvreau","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: Results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/bjd\/ljad022","article-title":"Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials","volume":"188","author":"Blauvelt","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"107720","DOI":"10.1016\/j.rmed.2024.107720","article-title":"Dupilumab responder types and predicting factors in patients with type 2 severe asthma: A real-world cohort study","volume":"231","author":"Bult","year":"2024","journal-title":"Respir. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","article-title":"Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): Two randomised, double-blind, placebo-controlled, phase 3 clinical trials","volume":"6","author":"Panettieri","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/09031936.00223411","article-title":"A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma","volume":"41","author":"Piper","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e13864","DOI":"10.1111\/cts.13864","article-title":"A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP\/anti-IL-13 NANOBODY(R) compound, in healthy volunteers","volume":"17","author":"Deiteren","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ralpha antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Allinne","year":"2020","journal-title":"Allergy"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e13899","DOI":"10.1111\/cts.13899","article-title":"Dupilumab: Mechanism of action, clinical, and translational science","volume":"17","author":"McCann","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"113102","DOI":"10.1016\/j.intimp.2024.113102","article-title":"Development of a novel humanized anti-TSLP monoclonal antibody, QX008N, and exploration of combination therapy of anti-TSLP antibody and anti-IL-4R antibody","volume":"142","author":"Wang","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1073\/pnas.1220145110","article-title":"Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange","volume":"110","author":"Labrijn","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Shi, L., Yu, M., Jin, Y., Chen, P., Mu, G., Tam, S.H., Cho, M., Tornetta, M., Han, C., and Fung, M.C. (2024). A novel monoclonal antibody against human thymic stromal lymphopoietin for the treatment of TSLP-mediated diseases. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1442588"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6720","DOI":"10.4049\/jimmunol.178.11.6720","article-title":"Cutting edge: Direct action of thymic stromal lymphopoietin on activated human CD4+ T cells","volume":"178","author":"Rochman","year":"2007","journal-title":"J. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/intimm\/3.6.571","article-title":"IL-1 up-regulates the expression of cytokine receptors on a factor-dependent human hemopoietic cell line, TF-1","volume":"3","author":"Kitamura","year":"1991","journal-title":"Int. Immunol."},{"key":"ref_61","unstructured":"Rommelaere, H., Brig\u00e9, A., Cornelis, S., Dombrecht, B., Lorent, E., Rieger, M., Soos, T., Park, J., Weigle, B., and Erb, K. (2021). Polypeptides Comprising Immunoglobulin Single Variable Domains Targeting Il-13 And TSLP. (WO 2021\/116182 A1)."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.4049\/jimmunol.1601497","article-title":"Lipopolysaccharide-Elicited TSLPR Expression Enriches a Functionally Discrete Subset of Human CD14+ CD1c+ Monocytes","volume":"198","author":"Borriello","year":"2017","journal-title":"J. Immunol."},{"key":"ref_63","first-page":"1098","article-title":"Extending human IgG half-life using structure-guided design","volume":"10","author":"Booth","year":"2018","journal-title":"mAbs"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"12161","DOI":"10.1128\/JVI.75.24.12161-12168.2001","article-title":"Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1","volume":"75","author":"Hezareh","year":"2001","journal-title":"J. Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/jcph.6115","article-title":"Phase 1 Safety and Pharmacokinetics Study of TAVO101, an Anti-Human Thymic Stromal Lymphopoietin Antibody for the Treatment of Allergic Inflammatory Conditions","volume":"65","author":"Han","year":"2024","journal-title":"J. Clin. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/ni.2182","article-title":"Divergent expression patterns of IL-4 and IL-13 define unique functions in allergic immunity","volume":"13","author":"Liang","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2025.01.017","article-title":"Targeting alarmins in asthma: From bench to clinic","volume":"155","author":"Akenroye","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cyto.2015.05.008","article-title":"The differential expression of IL-4 and IL-13 and its impact on type-2 immunity","volume":"75","author":"Bao","year":"2015","journal-title":"Cytokine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1084\/jem.189.10.1565","article-title":"Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses","volume":"189","author":"McKenzie","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma","volume":"385","author":"Wechsler","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/psp4.12136","article-title":"Exploratory Population PK Analysis of Dupilumab, a Fully Human Monoclonal Antibody Against IL-4Ralpha, in Atopic Dermatitis Patients and Normal Volunteers","volume":"5","author":"Kovalenko","year":"2016","journal-title":"CPT Pharmacomet. Syst. Pharmacol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/22\/1747\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T11:16:48Z","timestamp":1762514208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/22\/1747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":71,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["cells14221747"],"URL":"https:\/\/doi.org\/10.3390\/cells14221747","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]}}}